Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Indian J Med Res ; 146(5): 646-653, 2017 11.
Article in English | MEDLINE | ID: mdl-29512608

ABSTRACT

Background & objectives: Polyethylene terephthalate (PET) graft, designed and developed at our institute for vascular reconstruction, is porous to promote optimal incorporation and neointima formation, requiring pre-clotting or biomodification by sealing the pores before implantation. The objective of this study was to characterize, test and perform preclinical evaluation of hydrogel (alginate dialdehyde cross-linked gelatin) sealed fluoropassivated PET vascular prosthesis in pig model, so as to avoid pre-clotting, for its safety and efficacy before employing the indigenous and less expensive graft for clinical use. Methods: Hydrogel sealed, fluoropassivated PET vascular prosthesis were tested for haemocompatibility and toxicity followed by small animal toxicology tests and in vivo experiments in pigs receiving implantation at thoracic aorta. All 33 animals received test as well as control grafts with a plan for phased explantation at 2, 12 and 26 weeks. All animals underwent completion angiogram at the end of procedure as well as before graft explantation. Results: Haemocompatibility tests for haemolysis and toxicity tests showed no adverse events in tested mice and rabbits. Completion angiogram showed intact anastamosis and patent graft in each animal in post-operative period and at explantation. Gross and histopathological examination showed well-encapsulated grafts, clean glistening neointima and no evidence of thrombus in both test and control grafts. Interpretation & conclusions: Hydrogel sealed, fluoropassivated PET vascular prosthesis was found non-toxic, haemocompatible and remained patent in in vivo studies at planned intervals.


Subject(s)
Aorta, Thoracic/surgery , Blood Vessel Prosthesis , Polyethylene Terephthalates/therapeutic use , Vascular Remodeling/drug effects , Alginates/therapeutic use , Animals , Aorta, Thoracic/pathology , Aorta, Thoracic/transplantation , Blood Vessel Prosthesis/adverse effects , Gelatin/therapeutic use , Glucuronic Acid/therapeutic use , Hexuronic Acids/therapeutic use , Humans , Hydrogels/therapeutic use , Mice , Polyethylene Terephthalates/chemistry , Rabbits , Rifampin/pharmacology , Swine
2.
J Biomed Mater Res B Appl Biomater ; 105(7): 2145-2152, 2017 10.
Article in English | MEDLINE | ID: mdl-27417409

ABSTRACT

Glutaraldehyde treated bovine pericardium is extensively used in cardiovascular surgery. However, frequent occurrence of failure modes, such as calcification and structural failure, has hard pressed the need for finding an alternate technology. Decellularized bovine pericardium is an emerging technology. Mildly cross-linked decellularized bovine pericardium promotes positive remodeling with insignificant calcification and acute inflammation. In the present study, mildly cross-linked decellularized bovine pericardium was evaluated as a cardiovascular patch by studying mechanical strength as well as graft remodeling, resistance to calcific degeneration and inflammatory response using long duration porcine aortic implantation. It was observed that decellularized bovine pericardium, although thinner and less elastic had equivalent tensile properties such as tensile strength and stiffness when compared to commercially available glutaraldehyde-treated bovine pericardium. It showed the potential for site appropriate remodeling evidenced by host cell incorporation, thinner neointima, graft degradation, and neocollagenisation making it suitable for vascular patch application, whereas glutaraldehyde-treated pericardium failed to integrate with host tissue through timely degradation and host cell incorporation or neocollagenization. Conversely, it elicited persistent acute inflammation and produced calcification. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 2145-2152, 2017.


Subject(s)
Aorta , Extracellular Matrix , Neointima , Pericardium/chemistry , Animals , Aorta/metabolism , Aorta/pathology , Aorta/surgery , Cattle , Extracellular Matrix/chemistry , Extracellular Matrix/transplantation , Female , Glutaral/chemistry , Male , Swine
3.
J Biomed Mater Res A ; 101(8): 2202-9, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23281204

ABSTRACT

Decellularised tissue produces a variety of host responses ranging from constructive remodeling to scarring on account of its differences in the source of tissue, processing or sterilization methods. In this study, in vivo regeneration induced by decellularised bovine pericardium with or without mild glutaraldehyde crosslinking was studied in relation to its immune and inflammatory response using rat abdominal regeneration model. Mild glutaraldehyde crosslinking was done to subdue inflammatory and immune response without compromising host cell incorporation and graft remodeling. Evaluations were done at both 21 and 90 days. Un-crosslinked decellularised bovine pericardium showed more intense macrophage response predominantly of M2 phenotype at 90 days indicating chronic inflammatory response compared to mildly crosslinked group. This group also showed significant increase in plasma cell and lymphocyte count indicating immune stimulation. Lymphocyte transformation test detected presence of bovine pericardial antigen sensitized lymphocytes at both periods in un-crosslinked group. Lymphocytes from mildly crosslinked group failed to respond in this test at both periods. Significantly higher antibody response was also noted at both periods in un-crosslinked group. However, abdominal wall regeneration was observed only in animals implanted with un-crosslinked decellularised bovine pericardium at 90 days. From the above findings, it is inferred that un-crosslinked decellularised bovine pericardium produced significant chronic inflammatory response at 90 days and stimulated both humoral and cell mediated immune response in comparison to mildly crosslinked decellularised bovine pericardium. Yet this group produced skeletal muscle formation within graft at 90 days.


Subject(s)
Bioprosthesis , Inflammation/immunology , Pericardium/immunology , Abdomen/physiology , Adaptive Immunity , Animals , Bioprosthesis/adverse effects , Cattle , Cell Line , Cross-Linking Reagents/chemistry , Glutaral/chemistry , Lymphocytes/immunology , Macrophages/immunology , Pericardium/chemistry , Rats , Regeneration
4.
Toxicol Int ; 19(1): 51-8, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22736904

ABSTRACT

Glutaraldehyde-stabilized bovine pericardium is used for clinical application since 1970s because of its desirable features such as less immunogenicity and acceptable durability. However, a propensity for calcification is reported on account of glutaraldehyde treatment. In this study, commercially available glutaraldehyde cross-linked bovine pericardium was evaluated for its in vitro cytotoxic effect, macrophage activation, and in vivo toxic response in comparison to decellularized bovine pericardium. Glutaraldehyde-treated bovine pericardium and its extract were observed to be cytotoxic and it also caused significant inflammatory cytokine release from activated macrophages. Significant antibody response, calcification response, necrotic, and inflammatory response were noticed in glutaraldehyde-treated bovine pericardium in comparison to decellularized bovine pericardium in a rat subcutaneous implantation model. Glutaraldehyde-treated bovine pericardium also failed in acute systemic toxicity testing and intracutaneous irritation testing as per ISO 10993. With respect to healing and implant remodeling, total lack of host tissue incorporation and angiogenesis was noticed in glutaraldehyde-treated bovine pericardium compared to excellent host fibroblast incorporation and angiogenesis within the implant in decellularized bovine pericardium. In conclusion, using in vitro and in vivo techniques, this study has demonstrated that glutaraldehyde-treated bovine pericardium elicits toxic response compared to decellularized bovine pericardium which is not congenial for long-term implant performance.

5.
J Biomed Mater Res A ; 97(3): 311-20, 2011 Jun 01.
Article in English | MEDLINE | ID: mdl-21448995

ABSTRACT

Gluteraldehyde stabilized bovine pericardium is used for clinical application since 1970s because of its desirable features such as less immunogenicity and acceptable durability. However, a propensity for calcification and long term implant failure is reported because of gluteraldehyde treatment. There is also failure of implant to integrate into host tissue because of its resistance to tissue remodeling. Decellularized bovine pericardium, a potential alternative allows tissue remodeling but it has problems such as immunogenicity and chronic inflammatory response. In this study, decellularized bovine pericardium was subjected to short duration, low concentration gluteraldehyde cross-linking at two levels and its biological response (both in vitro and in vivo) was compared with un-crosslinked decellularized bovine pericardium and fully crosslinked normal bovine pericardium. It was observed that both un-crosslinked and partially crosslinked decellularized bovine pericardium to be non-cytotoxic and it caused significantly less inflammatory cytokine release such as TNF alpha and IL1beta from activated macrophages. Among all groups, short duration 0.2% Gluteraldehyde treated decellularized bovine pericardium showed significantly less antibody response and inflammatory response compared to un-crosslinked decellularized pericardium, short duration 0.6% gluteraldehyde treated decellularized bovine pericardium or completely cross linked bovine pericardium in juvenile rat subcutaneous implantation model. Moreover, short duration 0.2% gluteraldehyde crosslinked decellularized bovine pericardium showed minimum calcification, better host fibroblast incorporation, new collagen deposition and angiogenesis within the implant. These attributes may finally lead to better implant remodeling and sustained implant function during clinical use.


Subject(s)
Bioprosthesis , Cross-Linking Reagents/chemistry , Glutaral/chemistry , Pericardium/chemistry , Animals , Antibody Formation , Calcinosis , Cattle , Cell Line , Cell Survival , Collagenases/metabolism , Humans , Macrophages/immunology , Male , Pericardium/immunology , Pericardium/metabolism , Rats , Rats, Wistar
6.
Biomaterials ; 31(15): 4382-91, 2010 May.
Article in English | MEDLINE | ID: mdl-20189244

ABSTRACT

This study reports on a dual drug-eluting stent (DDES) that has an anti-proliferative and an anti-thrombotic in a biodegradable polymer-coated onto a cobalt-chromium stent. The DDES was prepared by spray coating the bare metal stent with a biodegradable polymer loaded with sirolimus and triflusal, to treat against restenosis and thrombosis, respectively. The 2-layered dual-drug coated stent was characterized in vitro for surface properties before and after expansion, as well as for possible delamination by cross-sectioning the stent in vitro. The in vitro anti-platelet behavior of the triflusal-loaded films was investigated by using dynamic platelet adhesion measurements. Additionally, the in vitro degradation and release study of the films and the stents w/single sirolimus and dual sirolimus-triflusal in different formulations were examined. Finally, in vivo studies (in a porcine carotid artery model) were performed for acute thrombosis, inflammation and restenosis at 30 days. The in vitro results show DDES can sustain release both anti-proliferation drug (sirolimus) and anti-thrombosis drug (triflusal), two drugs were controlled in different rates to effectively reduce thrombosis and proliferation at the same time. In vivo results show a significant reduction in restenosis with dual-drug eluting stent compared with the controls (a bare metal stent, a sirolimus coated and a pure polymer-coated stent). The reduction in restenosis with a dual sirolimus-triflusal eluting stent is associated with an inhibition of inflammation, especially thrombus formation, suggesting that such dual-drug eluting stents have a role to play for the treatment of coronary artery disease.


Subject(s)
Antibiotics, Antineoplastic , Drug-Eluting Stents , Hyperplasia/drug therapy , Platelet Aggregation Inhibitors , Salicylates , Sirolimus , Thrombosis/drug therapy , Animals , Antibiotics, Antineoplastic/chemistry , Antibiotics, Antineoplastic/pharmacology , Antibiotics, Antineoplastic/therapeutic use , Coated Materials, Biocompatible/chemistry , Coated Materials, Biocompatible/therapeutic use , Drug Delivery Systems , Humans , Materials Testing , Platelet Adhesiveness/drug effects , Platelet Aggregation Inhibitors/chemistry , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation Inhibitors/therapeutic use , Salicylates/chemistry , Salicylates/pharmacology , Salicylates/therapeutic use , Sirolimus/chemistry , Sirolimus/pharmacology , Sirolimus/therapeutic use , Surface Properties , Swine
7.
J Interv Cardiol ; 22(5): 466-78, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19627432

ABSTRACT

The aim of this article was to study the effect of dual drug-eluting stent (DES) on both restenosis and thrombosis in a porcine coronary artery model. This study reports on the use of two drugs coated on the stent to simultaneously minimize both restenosis and thrombosis. The DES was prepared by spray coating a bare metal stent with a biodegradable polymer loaded with sirolimus and triflusal, to treat against restenosis and thrombosis, respectively. The two-layered dual drug-coated stent was characterized in vitro for surface properties before and after expansion, as well as for possible delamination by cross-sectioning the stent in vitro. In vivo animal studies (in a pig model) were then performed for acute thrombosis, inflammation, and restenosis. The results show a significant reduction in restenosis with a stent coated with both drugs compared with the controls (a bare metal stent, a sirolimus-coated, and a pure polymer-coated stent). The reduction in restenosis with a sirolimus/triflusal-eluting stent is associated with an inhibition of inflammation and thrombus formation, suggesting that such dual DES have a role to play for the treatment of coronary artery diseases.


Subject(s)
Coronary Restenosis/surgery , Coronary Vessels/surgery , Drug-Eluting Stents/adverse effects , Thrombosis/etiology , Animals , Blood Vessel Prosthesis/adverse effects , Blood Vessel Prosthesis Implantation/adverse effects , Blood Vessel Prosthesis Implantation/instrumentation , Chromium Alloys/therapeutic use , Coronary Restenosis/prevention & control , Coronary Vessels/drug effects , Disease Models, Animal , Drug Therapy, Combination , Immunosuppressive Agents/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Prosthesis Design , Salicylates/therapeutic use , Sirolimus/therapeutic use , Swine , Treatment Outcome
8.
Int J Cardiol ; 131(3): 415-7, 2009 Jan 24.
Article in English | MEDLINE | ID: mdl-18006162

ABSTRACT

DES has made stenting a successful treatment modality. Still problems exists such as late thrombosis and continued neo-intimal proliferation. Blood flow affects the drug retained in the stent and subsequently on the time frame of vascular healing. To find out drug release kinetics from DES implanted in two different flow conditions, DES were implanted in porcine carotid artery and coronary artery. The drug release kinetics was found out by estimating the drug retained in the stent at different time periods. Through this study it is shown that DES in the coronary artery has a T1/2 of 24 days compared to 2 days in the carotid artery. The difference in T1/2 is attributed to the difference in flow as estimated using Hagen-Poiseuille equation. Evaluation of DES through heterotopic implantation may yield false results due to flow discrepancy. Moreover flow conditions should also be considered while designing the drug matrix to have optimum clinical efficacy.


Subject(s)
Carotid Arteries , Cerebrovascular Circulation , Coronary Circulation , Coronary Vessels , Drug-Eluting Stents , Paclitaxel/pharmacokinetics , Animals , In Vitro Techniques , Swine , Time Factors
9.
Cell Biochem Biophys ; 47(1): 65-72, 2007.
Article in English | MEDLINE | ID: mdl-17406060

ABSTRACT

Given that vascular endothelial cells play an important role in the modulation of vascular structure and function, we hypothesized that endocardial endothelial cells (EECs) may have a modulator role in regulating the cardiac interstitial cells. Endocardial endothelial cells were isolated from freshly collected pig hearts and cardiac fibroblasts were isolated from 3- to 4-d-old Wistar rats. Fibroblasts were cultured in the presence or absence of conditioned medium from EECs. Proliferation of cardiac fibroblasts was measured by the incorporation of [3H]- Thymidine and collagen synthesis was assayed by the incorporation of [3H]-Proline. To determine the involvement of signaling mediators, in separate experiments, cardiac fibroblasts were incubated with BQ123 (selective ETA receptor antagonist), PD142893 (nonselective ETA/ETB receptor antagonist), Bis-indolylmaleimide (PKC inhibitor), PD 098059 (MEK inhibitor), or neutralizing anti-transforming growth factor (TGF)-beta-antibody. Endocardial endothelium-derived factors endothelin (ET)-1, TGF-beta, and Angiotensin (Ang)-II in the conditioned medium were assayed by enzyme-linked immunosorbent assay using commercially available kits. We report here evidence that suggest that endocardial endothelial cells stimulate both proliferation and collagen synthesis of cardiac fibroblasts. The response seems to be mediated by endothelin through its ETA receptor. Our results also indicate that protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) pathways are essential for the EEC-induced proliferation of cardiac fibroblasts.


Subject(s)
Collagen/metabolism , Endocardium/metabolism , Endothelial Cells/cytology , Endothelium, Vascular/metabolism , Myocardium/metabolism , Animals , Cell Line , Cell Proliferation , Culture Media, Conditioned/metabolism , Endothelial Cells/metabolism , Enzyme Inhibitors/pharmacology , Fibroblasts/metabolism , Protein Kinase C/metabolism , Rats , Rats, Wistar , Transforming Growth Factor beta/metabolism
10.
Biomaterials ; 26(32): 6335-42, 2005 Nov.
Article in English | MEDLINE | ID: mdl-15919113

ABSTRACT

Wound dressings that can be formed in situ offer several advantages over the use of preformed dressings such as conformability without wrinkling or fluting in the wound bed, ease of application and improved patient compliance and comfort. Here we describe such an in situ forming hydrogel wound dressing from gelatin, oxidized alginate and borax. Periodate oxidized alginate rapidly cross-links proteins such as gelatin in the presence of borax to give in situ forming hydrogels that are both non-toxic and biodegradable. The composite matrix has the haemostatic effect of gelatin, the wound healing-promoting feature of alginate and the antiseptic property of borax to make it a potential wound dressing material. The hydrogel was found to have a fluid uptake of 90% of its weight which would prevent the wound bed from accumulation of exudates. The water vapour transmission rate (WVTR) of the hydrogel was found to be 2686+/-124 g/m2/day indicating that the hydrogel can maintain a moist environment over wound bed in moderate to heavily exuding wound which would enhance epithelial cell migration during the healing process. The wound healing efficacy of hydrogel was evaluated in experimental full thickness wounds using a rat model which demonstrated that within 2 weeks, the wound covered with gel was completely filled with new epithelium without any significant adverse reactions. These in situ forming hydrogels fulfil many critical elements desirable in a wound dressing material.


Subject(s)
Alginates/therapeutic use , Bandages, Hydrocolloid , Gelatin/therapeutic use , Wound Healing/drug effects , Wounds, Stab/drug therapy , Wounds, Stab/pathology , Alginates/chemistry , Animals , Biocompatible Materials/analysis , Biocompatible Materials/chemistry , Equipment Design , Equipment Failure Analysis , Gelatin/chemistry , Glucuronic Acid/chemistry , Glucuronic Acid/therapeutic use , Hexuronic Acids/chemistry , Hexuronic Acids/therapeutic use , Hydrogels/chemistry , Hydrogels/therapeutic use , Male , Materials Testing , Oxidation-Reduction , Rats , Rats, Wistar , Skin/drug effects , Skin/injuries , Skin/pathology , Treatment Outcome
11.
Biomaterials ; 25(24): 5557-63, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15142738

ABSTRACT

Bioactive hemostats and wound dressings consist of either inherently active materials or act as delivery vehicles which contain such materials. Fibrin is a natural hemostat and scaffold, guiding the direction of wound contraction and closure. In order to improve the ease of application of liquid fibrin glue, we have made a freeze-dried form of polymerized fibrin that supports hemostasis and wound healing. The bleeding from the middle ear artery of rabbits was found to be arrested instantaneously on application of fibrin sheets, even when the animal was heparinized systemically. As the fibrin sheet was found to be fragile, gelatin was incorporated to the sheet and thus the mechanical stability was improved without compromising the hemostatic effect. The efficacy of the fabricated fibrin and fibrin-gelatin sheets to seal traumatized rat liver was compared with commercially available hemostats, Abgel (cross-linked gelatin) and Surgicel (cross-linked cellulose). Tissue compatibility of all the hemostats was studied by analyzing the liver tissue 15 days after application. While the hemostatic effect was best with fibrin and fibrin-gelatin sheets, both Surgicel and Abgel were not capable of arresting the bleeding quickly. Gross analysis of tissue on the 15th day of application, visibly, Abgel was not only degraded but resulted in severe adhesions of internal organs and histologically capsule formation around the implant was evident. Though Surgicel was also seen as cream soft material on the site of application that joined two pieces of liver, there was no adhesion of other internal organs and histologically, immune reaction and foreign-body-type giant cells were present in large amounts. Fibrin was not found grossly on application site whereas fibrin-gelatin was seen as a small white spot. Granulation tissue formation and cell migration into the fibrin-based sheets were evident, and therefore, fibrin-based sheets are not only efficient hemostats but showed optimum degradation and wound healing.


Subject(s)
Fibrin/chemistry , Hemostatics , Animals , Biocompatible Materials , Liver/pathology , Rabbits , Wound Healing
12.
Biomaterials ; 23(14): 3023-31, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12069345

ABSTRACT

Fibrin sealant or fibrin glue (FG) has been found to be effective as a wound-healing substance in surgery. However, its role in bone fracture healing and osseous tissue response is not fully understood. This ambiguity questions the potential of FG as an inductive protein. The present study was undertaken to evaluate the osteoinductive property of FG when coated with calcium phosphate and glass ceramics and implanted in the extraskeletal site of male Swiss albino mice. Implant materials used for this study were hydroxyapatite (HA) porous granules (300-350 microm), bioactive glass system (BGS)-AW type and calcium phosphate calcium silicate system (HABGS) non-porous granules (300-350 microm). Uncoated granules (control) and coated granules with 2.5 mg FG and 5 mg FG were implanted in the quadriceps muscle of mice and sacrificed after 28 days. Histologically, HA, BGS and HABGS implanted animal groups showed good healing response. However, neo-osteogenesis was observed only in the BGS and HABGS granules impregnated with FG. Furthermore, bone formation was observed to be more conspicuous in 5 mg FG coated BGS and HABGS granules when compared with 2.5 mg FG coated BGS and HABGS granules. Fluorochrome labeling proved that mineralization had already started by day 15 with FG preadsorbed BGS and HABGS granules. On the contrary, the uncoated granules did not show any de novo bone formation. This experimental study provides an evidence of the positive role of FG as a potential osteoinductive biologic tissue adhesive.


Subject(s)
Coated Materials, Biocompatible/pharmacology , Fibrin Tissue Adhesive/pharmacology , Osteogenesis , Animals , Bone Substitutes , Calcium Phosphates , Ceramics , Fibrin Tissue Adhesive/chemistry , Hydroxyapatites , Implants, Experimental , Male , Mice , Microscopy, Electron, Scanning , Particle Size , Surface Properties
13.
J Biochem Biophys Methods ; 51(2): 129-38, 2002 Apr 18.
Article in English | MEDLINE | ID: mdl-12062112

ABSTRACT

The production of antibodies and its purification from mammalian blood has been found low yielding and laborious. Therefore, anti snake venom antibodies for therapeutic use is obtained mostly as polyvalent whole serum or partially purified polyvalent immunoglobulin. The side effects of anti snake venom (ASV) therapy are mainly serum sickness and renal failure, which may be reduced by using sufficiently pure antibodies. Therefore, we have standardized a simple method for production of purified antivenom. Here, we present the development of polyclonal antibodies against viper venom in hens and its isolation from the egg yolk of immunized birds. We have modified the reported methods of purification of immunoglobulin from egg yolk, and thus yielded 90% purity of the protein. The modified method involves only two steps, such as removal of lipids from the diluted egg yolk by a freeze-thaw cycle and centrifugation, followed by gel filtration on Biogel P-150. The advantages are that the process is very simple, and from one egg, 100+/-20 mg of pure immunoglobulin is obtained. The antibodies are present in the egg for up to 100 days after the immunization. Thus, using small amounts of venom, a large quantity of the immunoglobulin is obtained in a sufficiently pure form. The antigen binding ability of the pure antibody is found good by the Ouchterlony's double diffusion experiment.


Subject(s)
Antibodies/chemistry , Biochemistry/methods , Egg Yolk/chemistry , Viper Venoms/immunology , Animals , Antigen-Antibody Reactions , Chickens , Chromatography, Gel , Diffusion , Electrophoresis, Polyacrylamide Gel , Lipids/chemistry
14.
Life Sci ; 70(15): 1777-88, 2002 Mar 01.
Article in English | MEDLINE | ID: mdl-12002522

ABSTRACT

Several studies have demonstrated that excess of vitamin D3 is toxic particularly to vascular tissues. A notable pathological feature is arterial calcification. The nature of the toxic metabolite in hypervitaminosis D and the pathogenesis of arterial calcification are not clearly understood. The present study was undertaken to explore whether arterial calcification is a sequel of increased calcium uptake by arterial smooth muscle mediated by up regulation of vitamin D receptor in the cells in response to elevated circulating levels of vitamin D3 in serum. The experimental study was performed in 20 New Zealand white female rabbits aged 6 months. Animals in the test group were injected 10,000 IU of cholecalciferol intramuscularly twice a week for one month. Six control animals were given intra-muscular injections of plain cottonseed oil. Animals were sacrificed and aortas were examined for pathological lesions, 1,25-dihyroxyvitamin D3 (1,25(OH)2 D3) receptor levels and 45Ca uptake in smooth muscle cells. Serum samples collected at intervals were assayed for levels of 25-OH-D3 and calcium. The results showed that in animals given injections of cholecalciferol, serum levels of 25-OH-D3 were elevated. In four of these animals calcification and aneurysmal changes were seen in the aorta. Histological lesions comprised of fragmentation of elastic fibers as well as extensive loss of elastic layers. 1,25(OH)2 D3 receptor levels were up regulated and 45Ca uptake enhanced in aortas of animals which were given excessive vitamin D3. The evidences gathered suggest that excess vitamin D is arteriotoxic and that the vitamin induces arterial calcification through up regulation of 1,25(OH)2D3 receptor and increased calcium uptake in smooth muscle cells of the arteries.


Subject(s)
Aorta, Abdominal/metabolism , Aorta, Thoracic/metabolism , Cholecalciferol/toxicity , Muscle, Smooth, Vascular/metabolism , Receptors, Calcitriol/metabolism , Animals , Aorta, Abdominal/pathology , Aorta, Thoracic/pathology , Calcifediol/blood , Calcinosis/etiology , Calcinosis/pathology , Calcium/metabolism , Cells, Cultured , Cholecalciferol/administration & dosage , Female , Injections, Intramuscular , Muscle, Smooth, Vascular/ultrastructure , Rabbits , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...